Turning Point Brands Announces First Quarter 2022 Results
Turning Point Brands (TPB) reported Q1 2022 net sales of $100.9 million, down 6.3% year-over-year, despite a 10.1% sales increase in Zig-Zag and Stoker's products. Gross profit decreased 2.8% to $51.8 million, and net income fell 6.7% to $11.0 million. Adjusted EBITDA dropped 9.8% to $25.3 million. The NewGen segment faced a 37.1% sales decline due to regulatory impacts. Zig-Zag contributed significantly to growth, with an 11.4% increase in sales, while Stoker's saw an 8.4% increase. Despite challenges, the company maintains a strong balance sheet and continues share repurchases.
- Net sales for Zig-Zag and Stoker's products increased by 10.1%.
- Zig-Zag Products net sales rose 11.4% to $45.7 million.
- Stoker's Products net sales climbed 8.4% to $31.7 million.
- Stoker's Products gross profit increased 11.3% to $17.7 million.
- TPB maintains a strong balance sheet with total liquidity of $147.4 million.
- Overall net sales decreased by 6.3% year-over-year.
- Gross profit decreased 2.8% to $51.8 million.
- Net income decreased 6.7% to $11.0 million.
- Adjusted EBITDA fell 9.8% to $25.3 million.
- NewGen Products segment sales plummeted 37.1% due to regulatory impacts.
Q1 2022 vs. Q1 2021
-
Net sales decreased 6.3 percent to
$100.9 million - Net sales for Zig-Zag and Stoker’s Products increased 10.1 percent
-
Gross profit decreased 2.8 percent to
$51.8 million -
Net income decreased 6.7 percent to
$11.0 million -
Adjusted EBITDA decreased 9.8 percent to
(see Schedule A for a reconciliation to net income)$25.3 million -
Diluted EPS of
and Adjusted Diluted EPS of$0.55 as compared to$0.71 and$0.57 in the same period one year ago, respectively (see Schedule B for a reconciliation to Diluted EPS)$0.80
“Our first quarter results were in-line with our expectations as we continued to grow our market share for both Zig-Zag and Stoker’s while navigating a difficult consumer and regulatory environment to drive profitability in each of our segments, including NewGen. Sales decreased 6 percent from the previous year driven by a 37 percent decline in NewGen sales but showed double-digit growth excluding NewGen,” said
Continued
Zig-Zag Products Segment (45 percent of total net sales in the quarter)
For the first quarter, Zig-Zag Products net sales increased 11.4 percent to
For the quarter, the Zig-Zag Products segment gross profit increased 5.8 percent to
“Paper cones and Zig-Zag’s e-commerce business continued to drive the growth within our
Stoker’s Products Segment (32 percent of total net sales in the quarter)
For the first quarter, Stoker’s Products net sales increased 8.4 percent to
For the quarter, the Stoker’s Products segment gross profit increased 11.3 percent to
“Stoker’s delivered solid growth during the quarter led by continued market share gains in MST,” continued Purdy. “As mentioned above, with the backdrop of inflationary pressures impacting the consumer, Stoker’s is well positioned within its categories as a leading value brand.”
NewGen Products Segment (23 percent of total net sales in the quarter)
For the first quarter, NewGen Products net sales decreased 37.1 percent to
For the quarter, the NewGen Products segment gross profit decreased 37.7 percent to
“Our vape business remained profitable even with the expected weakness during the quarter as it continues to navigate challenges presented by the regulatory environment,” concluded Purdy. “Encouragingly, we continued to ramp our last mile logistics and distribution capabilities through the quarter. We will continue to adapt to the market environment as it goes through another transition period with the FDA expanding regulation of nicotine products. TPB’s applications for our vapor products remain under review.”
Recent Events
To give better visibility on our vape business, certain non-vape products’ sales along with the associated and other costs have been moved from the NewGen Products segment into our other TPB reporting segments. Specifically, Wild Hemp sales have been moved to the Zig-Zag Products segment where TPB’s other smoking products sales are recognized. Additionally, the Company’s FRE nicotine pouch products’ sales moved to the Stoker’s Products segment where TPB’s other smokeless products sales are recognized. Both were marginal contributors to the Company’s overall performance. In addition, certain personnel and other non-vape related costs previously allocated to the Nu-X subsegment related to marketing, new product development, product sourcing and other corporate functions moved from the NewGen Products segment primarily into the Corporate segment for reporting purposes. In effect, Nu-X operations are being absorbed by other TPB reporting segments and the NewGen Products segment now primarily represents operations related to our proprietary vape products and vape distribution business.
Performance Measures in the First Quarter
First quarter consolidated selling, general and administrative (“SG&A”) expenses were
The first quarter SG&A included the following notable items:
-
of restructuring expenses compared to none in the previous year$1.3 million -
of ERP / CRM scoping expenses compared to none in the previous year$0.3 million -
of stock options, restricted stock and incentive expense compared to$1.1 million in the year-ago period$1.5 million -
of transaction expenses compared to$0.4 million in the year-ago period$0.6 million -
of FDA PMTA-related expenses compared to$1.1 million in the year-ago period$0.3 million -
in outbound freight expense compared to$4.2 million in the year-ago period with the increase due to higher shipping costs on vapor products related to PACT Act implementation and higher freight costs across all segments$3.7 million -
from the accounting consolidation of Turning Point Brands Canada compared to$1.5 million in the year-ago period with the increase driven by the inclusion of the DVW acquisition in the current period$0.8
Total gross debt as of
During the quarter, the Company spent
2022 Outlook
TPB is maintaining the guidance provided on
Earnings Conference Call
As previously disclosed, a conference call with the investment community to review TPB’s financial results has been scheduled for
Non-GAAP Financial Measures
In addition to financial measures prepared in accordance with generally accepted accounting principles in
About
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements may generally be identified by the use of words such as "anticipate," "believe," "expect," "intend," "plan" and "will" or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. As a result, these statements are not guarantees of future performance and actual events may differ materially from those expressed in or suggested by the forward-looking statements. Any forward-looking statement made by TPB in this press release, its reports filed with the
Financial Statements Follow:
Consolidated Statements of Income | |||||||
(dollars in thousands except share data) | |||||||
(unaudited) | |||||||
Three Months Ended |
|||||||
2022 |
2021 |
||||||
Net sales | $ |
100,894 |
|
$ |
107,641 |
|
|
Cost of sales |
|
49,100 |
|
|
54,380 |
|
|
Gross profit |
|
51,794 |
|
|
53,261 |
|
|
Selling, general, and administrative expenses |
|
32,565 |
|
|
28,912 |
|
|
Operating income |
|
19,229 |
|
|
24,349 |
|
|
Interest expense, net |
|
5,196 |
|
|
4,486 |
|
|
Investment income |
|
(78 |
) |
|
(25 |
) |
|
Loss on extinguishment of debt |
|
- |
|
|
5,706 |
|
|
Income before income taxes |
|
14,111 |
|
|
14,182 |
|
|
Income tax expense |
|
3,340 |
|
|
2,654 |
|
|
Consolidated net income |
|
10,771 |
|
|
11,528 |
|
|
Net loss attributable to non-controlling interest |
|
(227 |
) |
|
(255 |
) |
|
Net income attributable to |
$ |
10,998 |
|
$ |
11,783 |
|
|
Basic income per common share: | |||||||
Net income attributable to |
$ |
0.60 |
|
$ |
0.62 |
|
|
Diluted income per common share: | |||||||
Net income attributable to |
$ |
0.55 |
|
$ |
0.57 |
|
|
Weighted average common shares outstanding: | |||||||
Basic |
|
18,257,695 |
|
|
19,093,961 |
|
|
Diluted |
|
21,749,510 |
|
|
22,665,067 |
|
|
Supplemental disclosures of statements of income information: | |||||||
Excise tax expense | $ |
5,709 |
|
$ |
8,789 |
|
|
FDA fees | $ |
124 |
|
$ |
170 |
|
|
Consolidated Balance Sheets | |||||||
(dollars in thousands except share data) | |||||||
(unaudited) | |||||||
ASSETS | 2022 |
2021 |
|||||
Current assets: | |||||||
Cash | $ |
126,045 |
|
$ |
128,320 |
|
|
Accounts receivable, net of allowances of |
|
9,450 |
|
|
6,496 |
|
|
Inventories |
|
105,858 |
|
|
87,607 |
|
|
Other current assets |
|
25,663 |
|
|
26,746 |
|
|
Total current assets |
|
267,016 |
|
|
249,169 |
|
|
Property, plant, and equipment, net |
|
20,567 |
|
|
18,650 |
|
|
Deferred income taxes |
|
1,754 |
|
|
1,363 |
|
|
Right of use assets |
|
14,405 |
|
|
15,053 |
|
|
Deferred financing costs, net |
|
362 |
|
|
388 |
|
|
|
162,323 |
|
|
162,333 |
|
||
Other intangible assets, net |
|
87,022 |
|
|
87,485 |
|
|
Master Settlement Agreement (MSA) escrow deposits |
|
30,237 |
|
|
31,720 |
|
|
Other assets |
|
35,017 |
|
|
35,399 |
|
|
Total assets | $ |
618,703 |
|
$ |
601,560 |
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
Current liabilities: | |||||||
Accounts payable | $ |
29,464 |
|
$ |
7,361 |
|
|
Accrued liabilities |
|
29,921 |
|
|
32,937 |
|
|
Other current liabilities |
|
38 |
|
|
38 |
|
|
Total current liabilities |
|
59,423 |
|
|
40,336 |
|
|
Notes payable and long-term debt |
|
414,791 |
|
|
414,172 |
|
|
Lease liabilities |
|
12,625 |
|
|
13,336 |
|
|
Total liabilities |
|
486,839 |
|
|
467,844 |
|
|
Commitments and contingencies | |||||||
Stockholders' equity: | |||||||
Preferred stock; |
|
- |
|
|
- |
|
|
Common stock, voting, |
|
198 |
|
|
197 |
|
|
Common stock, nonvoting, |
|
- |
|
|
- |
|
|
Additional paid-in capital |
|
109,073 |
|
|
108,811 |
|
|
Cost of repurchased common stock (1,605,632 shares at |
|
(59,491 |
) |
|
(48,869 |
) |
|
Accumulated other comprehensive loss |
|
(1,326 |
) |
|
(195 |
) |
|
Accumulated earnings |
|
81,327 |
|
|
71,460 |
|
|
Non-controlling interest |
|
2,083 |
|
|
2,312 |
|
|
Total stockholders' equity |
|
131,864 |
|
|
133,716 |
|
|
Total liabilities and stockholders' equity | $ |
618,703 |
|
$ |
601,560 |
|
|
Consolidated Statements of Cash Flows | |||||||
(dollars in thousands) | |||||||
(unaudited) | |||||||
Three Months Ended |
|||||||
2022 |
2021 |
||||||
Cash flows from operating activities: | |||||||
Consolidated net income | $ |
10,771 |
|
$ |
11,528 |
|
|
Adjustments to reconcile net income to net cash provided by operating activities: | |||||||
Loss on extinguishment of debt |
|
- |
|
|
5,706 |
|
|
Loss (gain) on sale of property, plant, and equipment |
|
1 |
|
|
(2 |
) |
|
Depreciation expense |
|
871 |
|
|
788 |
|
|
Amortization of other intangible assets |
|
463 |
|
|
477 |
|
|
Amortization of deferred financing costs |
|
645 |
|
|
604 |
|
|
Deferred income tax (benefit) expense |
|
(34 |
) |
|
552 |
|
|
Stock compensation expense |
|
1,159 |
|
|
1,498 |
|
|
Noncash lease (income) expense |
|
(5 |
) |
|
6 |
|
|
Gain on investments |
|
(14 |
) |
|
(13 |
) |
|
Changes in operating assets and liabilities: | |||||||
Accounts receivable |
|
(2,958 |
) |
|
2,735 |
|
|
Inventories |
|
(18,258 |
) |
|
(12,461 |
) |
|
Other current assets |
|
1,081 |
|
|
1,283 |
|
|
Other assets |
|
382 |
|
|
464 |
|
|
Accounts payable |
|
22,101 |
|
|
14,882 |
|
|
Accrued liabilities and other |
|
(3,165 |
) |
|
(3,806 |
) |
|
Net cash provided by operating activities | $ |
13,040 |
|
$ |
24,241 |
|
|
Cash flows from investing activities: | |||||||
Capital expenditures | $ |
(2,787 |
) |
$ |
(842 |
) |
|
Restricted cash, MSA escrow deposits |
|
(8,468 |
) |
|
(14,920 |
) |
|
Proceeds on the sale of property, plant and equipment |
|
1 |
|
|
2 |
|
|
Net cash used in investing activities | $ |
(11,254 |
) |
$ |
(15,760 |
) |
|
Cash flows from financing activities: | |||||||
Proceeds from Senior Secured Notes | $ |
- |
|
$ |
250,000 |
|
|
Payments of 2018 first lien term loan |
|
- |
|
|
(130,000 |
) |
|
Settlement of interest rate swaps |
|
- |
|
|
(3,573 |
) |
|
Payment of dividends |
|
(1,022 |
) |
|
(958 |
) |
|
Payments of financing costs |
|
- |
|
|
(6,614 |
) |
|
Exercise of options |
|
245 |
|
|
425 |
|
|
Redemption of options |
|
- |
|
|
(1,466 |
) |
|
Redemption of performance restricted stock units |
|
(1,141 |
) |
|
- |
|
|
Common stock repurchased |
|
(10,622 |
) |
|
(5,733 |
) |
|
Net cash provided by (used in) financing activities | $ |
(12,540 |
) |
$ |
102,081 |
|
|
Net (decrease) increase in cash | $ |
(10,754 |
) |
$ |
110,562 |
|
|
Effect of foreign currency translation on cash | $ |
(3 |
) |
$ |
101 |
|
|
Cash, beginning of period: | |||||||
Unrestricted |
|
128,320 |
|
|
41,765 |
|
|
Restricted |
|
15,155 |
|
|
35,074 |
|
|
Total cash at beginning of period |
|
143,475 |
|
|
76,839 |
|
|
Cash, end of period: | |||||||
Unrestricted |
|
126,045 |
|
|
167,361 |
|
|
Restricted |
|
6,673 |
|
|
20,141 |
|
|
Total cash at end of period | $ |
132,718 |
|
$ |
187,502 |
|
|
Non-GAAP Financial Measures
To supplement our financial information presented in accordance with generally accepted accounting principles in
We define “EBITDA” as net income before interest expense, loss on extinguishment of debt, provision for income taxes, depreciation and amortization. We define “Adjusted EBITDA” as net income before interest expense, loss on extinguishment of debt, provision for income taxes, depreciation, amortization, other non-cash items and other items that we do not consider ordinary course in our evaluation of ongoing operating performance. We define “Adjusted diluted EPS” as diluted earnings per share excluding items that we do not consider ordinary course in our evaluation of ongoing operating performance. We define “Adjusted Operating Income” as operating income excluding other non-cash items and other items that we do not consider ordinary course in our evaluation of ongoing operating performance.
Non-
In accordance with
Schedule A | |||||
Reconciliation of GAAP Net Income to Adjusted EBITDA | |||||
(dollars in thousands) | |||||
(unaudited) | |||||
Three Months Ended |
|||||
|
|||||
2022 |
2021 |
||||
Net income attributable to |
$ |
10,998 |
$ |
11,783 |
|
Add: | |||||
Interest expense, net |
|
5,196 |
|
4,486 |
|
Loss on extinguishment of debt |
|
- |
|
5,706 |
|
Income tax expense |
|
3,340 |
|
2,654 |
|
Depreciation expense |
|
871 |
|
788 |
|
Amortization expense |
|
463 |
|
477 |
|
EBITDA | $ |
20,868 |
$ |
25,894 |
|
Components of Adjusted EBITDA | |||||
Corporate restructuring (a) |
|
1,332 |
|
- |
|
ERP/CRM (b) |
|
330 |
|
- |
|
Stock options, restricted stock, and incentives expense (c) |
|
1,159 |
|
1,498 |
|
Transactional expenses (d) |
|
425 |
|
607 |
|
FDA PMTA (e) |
|
1,139 |
|
- |
|
Adjusted EBITDA | $ |
25,253 |
$ |
27,999 |
|
(a) Represents costs associated with corporate restructuring, including severance. | |||||
(b) Represents cost assosicated with scoping new ERP and CRM systems. | |||||
(c) Represents non-cash stock options, restricted stock, incentives expense and Solace performance stock units. | |||||
(d) Represents the fees incurred for transaction expenses. | |||||
(e) Represents costs associated with applications related to FDA premarket tobacco product application ("PMTA"). |
Schedule B | ||||||
Reconciliation of GAAP diluted EPS to Adjusted diluted EPS | ||||||
(dollars in thousands except share data) | ||||||
(unaudited) | Three Months Ended | |||||
2022 |
2021 |
|||||
GAAP EPS | $ |
0.55 |
$ |
0.57 |
|
|
Corporate restructuring (a) |
|
0.05 |
|
- |
|
|
ERP/CRM (b) |
|
0.01 |
|
0.05 |
|
|
Loss on extinguishment of debt (c) |
|
- |
|
0.20 |
|
|
Stock options, restricted stock, and incentives expense (d) |
|
0.04 |
|
0.05 |
|
|
Transactional expenses (e) |
|
0.01 |
|
0.02 |
|
|
FDA PMTA (f) |
|
0.04 |
|
- |
|
|
Tax (expense) benefit (g) |
|
0.01 |
|
(0.10 |
) |
|
Adjusted diluted EPS | $ |
0.71 |
$ |
0.80 |
|
|
Totals may not foot due to rounding | ||||||
(a) Represents costs associated with corporate restructuring, including severance, tax effected at the quarterly tax rate. | ||||||
(b) Represents cost assosicated with scoping new ERP and CRM systems tax effected at the quarterly tax rate. | ||||||
(c) Represents Loss on Extinguishment of Debt tax effected at the quarterly tax rate. | ||||||
(d) Represents non-cash stock options, restricted stock, incentives expense and Solace PRSUs tax effected at the quarterly tax rate. | ||||||
(e) Represents the fees incurred for transaction expenses tax effected at the quarterly tax rate. | ||||||
(f) Represents costs associated with applications related to the FDA PMTA tax effected at the quarterly tax rate. | ||||||
(g) Represents adjustment from quarterly tax rate to annual projected tax rate of |
Schedule C | |||||||||||||||||||||||
Reconciliation of GAAP Operating Income to Adjusted Operating Income | |||||||||||||||||||||||
(dollars in thousands) | |||||||||||||||||||||||
(unaudited) | |||||||||||||||||||||||
Consolidated | Zig-Zag Products | Stoker's Products | NewGen Products | ||||||||||||||||||||
1st Quarter | 1st Quarter | 1st Quarter | 1st Quarter | 1st Quarter | 1st Quarter | 1st Quarter | 1st Quarter | ||||||||||||||||
2022 |
2021 |
2022 |
2021 |
2022 |
2021 |
2022 |
2021 |
||||||||||||||||
Net sales | $ |
100,894 |
$ |
107,641 |
$ |
45,672 |
$ |
41,004 |
$ |
31,703 |
$ |
29,255 |
$ |
23,519 |
$ |
37,382 |
|||||||
Gross profit | $ |
51,794 |
$ |
53,261 |
$ |
26,343 |
$ |
24,896 |
$ |
17,686 |
$ |
15,892 |
$ |
7,765 |
$ |
12,473 |
|||||||
Operating income | $ |
19,229 |
$ |
24,349 |
$ |
18,737 |
$ |
19,437 |
$ |
13,506 |
$ |
12,255 |
$ |
678 |
$ |
2,006 |
|||||||
Adjustments: | |||||||||||||||||||||||
Corporate restructuring |
|
1,332 |
|
- |
|
- |
|
- |
|
- |
|
- |
|
- |
|
- |
|||||||
ERP/CRM |
|
330 |
|
- |
|
- |
|
- |
|
- |
|
- |
|
- |
|||||||||
Transactional expenses |
|
425 |
|
607 |
|
- |
|
- |
|
- |
|
- |
|
- |
|
- |
|||||||
FDA PMTA |
|
1,139 |
|
- |
|
- |
|
- |
|
- |
|
- |
|
- |
|
- |
|||||||
Adjusted operating income | $ |
22,455 |
$ |
24,956 |
$ |
18,737 |
$ |
19,437 |
$ |
13,506 |
$ |
12,255 |
$ |
678 |
$ |
2,006 |
|||||||
View source version on businesswire.com: https://www.businesswire.com/news/home/20220427005190/en/
Media Contacts
212.896.1204
rcona@kcsa.com
Investor Contacts
502.774.9238
ir@tpbi.com
Source:
FAQ
What were the financial results for Turning Point Brands in Q1 2022?
How did Zig-Zag and Stoker's products perform in Q1 2022?
What challenges did Turning Point Brands face in the regulatory environment?
What is the current liquidity position of Turning Point Brands?